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Abstract 
Some patients with autoimmune and inflammatory diseases treated with intravenous 
immunoglobulin G (IVIg) as a first line therapy are refractory. Identification of 
predictive biomarker(s) to segregate responders and non-responders to IVIg therapy 
remains critical. A number of biomarkers, particularly in Kawasaki disease, have 
shown potential for predicting response to IVIg. 
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Intravenous immunoglobulin (IVIg) is a pooled preparation of normal human 
immunoglobulin G (IgG) purified from the plasma of several thousand healthy 
donors. IVIg is one of the most highly solicited therapeutic molecules for the therapy 
of autoimmune and inflammatory diseases. Randomized clinical trials have 
demonstrated the therapeutic utility of IVIg in a wide range of diseases including 
Kawasaki disease (KD), immune thrombocytopenia (ITP), chronic inflammatory 
demyelinating polyneuropathy, anti-neutrophil cytoplasmic antibody-associated-
vasculitis, myasthenia gravis, dermatomyositis, Guillain-Barré syndrome (GBS), 
graft-versus-host disease and others. Several mutually nonexclusive mechanisms have 
been proposed for IVIg that include inhibition of innate and adaptive immune cell 
activation and their inflammatory mediators, and induction of anti-inflammatory cells 
and molecules. 
 
Nevertheless, IVIg is not a magic bullet. Even among the diseases where IVIg is 
recommended as a first line therapy, there are patients who do not respond. 
Identification of predictive biomarker(s) to segregate responders and non-responders 
remains a critical issue and the subject of intense research. The majority of studies 
have focused on KD, although other pathologies such as ITP and GBS have also been 
investigated. 
 
Identifying biomarkers to predict responders to IVIg therapy is important both for 
patients and the health-care system. Early identification of IVIg-resistant patients 
helps clinicians to promptly initiate alternative therapies, reducing the morbidity and 
also the cost associated with IVIg therapy. Further, it would also help in preventing 
the empirical use of IVIg, which is currently used for nearly 100 different pathologies.   
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KD is characterized by systemic vasculitis (mainly involving coronary arteries) in 
children. Preventing serious cardiac complications is the primary goal of treatment. 
High-dose IVIg treatment during the acute stage of KD is effective in preventing 
coronary artery lesions. Unfortunately, 10-20% of patients experience IVIg resistance, 
which is associated with poor coronary artery outcomes. Risk-scoring systems have 
been developed to predict resistance to initial IVIg treatment by taking into 
consideration age, illness duration and various blood and biochemical parameters 
such as platelet and neutrophil counts, alanine aminotransferase, and C-reactive 
protein (CRP). Although these scores have good specificity, their low sensitivity to 
predict IVIg resistance in other cohorts casts doubt on their universal applicability [1].  
 
Inflammatory mediators such as cytokines and chemokines are key players in the 
pathogenesis of autoimmune and inflammatory diseases. They stimulate immune and 
non-immune cells, program T cell differentiation and instruct homing of immune 
cells. Pre-IVIg levels of inflammatory mediators such as granulocyte-colony 
stimulating factor (G-CSF), IL-1β and IL-6 determine the responsiveness to IVIg 
[2,3,4]. The circulating levels of G-CSF were significantly higher (three-fold) in 
IVIg-nonresponsive patients [2] and were corroborated with significantly higher 
levels of polycythemia rubra vera 1 (PRV-1) and matrix metalloproteinase-8 (MMP-
8)	   [2,3]. As G-CSF stimulates granulopoiesis and granulocyte differentiation, these 
reports substantiated previous observations of significantly elevated neutrophils in 
IVIg-nonresponsive patients. In addition, the elevated levels of damage-associated 
molecular pattern molecules (DAMPs) such as high-mobility group protein B1 
(HMGB1), S100A8 and S100A9 were reported to predict poor response to IVIg [3]. 
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These DAMPs are released from stressed cells, and signal via receptor for advanced 
glycation end products (RAGE) and Toll-like receptors (TLR) to promote 
inflammatory responses from innate cells (Figure 1). S100A8 and A9 also regulate the 
adhesion of neutrophils and monocytes to endothelial cells, a process that is likely 
important in the vasculitis of KD.  
 
Genetic and epigenetic studies on the pathways that signal cytokine and chemokine 
production have been undertaken to provide molecular insight on the IVIg response. 
The majority of autoimmune diseases are characterized by the presence of high-
affinity autoantibodies that form immune complexes with auto-antigens and stimulate 
innate immune cells via Fcγ receptors (FcγR) to induce inflammatory mediators. A 
functional polymorphism in FCGR2A encoding an H131R substitution has been 
identified as a susceptibility locus for KD [5], confirming the role of FcγR signaling 
in the pathogenesis of KD. A family-based genetic study also confirmed this 
observation [6], but this polymorphism does not predict response to IVIg therapy.  
 
The recent study by Kuo et al. demonstrates that it is not the polymorphism in 
FCGR2A, but rather epigenetic changes, in particular hypomethylation in five CpG 
sites that predicts IVIg resistance	   [7]. Therefore, the threshold of activation of 
FcγRIIA determines the responsiveness to IVIg. FcγRIIA is highly expressed on 
innate immune cells (including macrophages, dendritic cells and neutrophils), 
therefore stimulation via FcγRIIA leads to the secretion of various inflammatory 
cytokines and chemokines (Figure 1). Thus, this data provides mechanistic insight 
into previous reports of elevated levels of pro-inflammatory cytokines and 
unresponsiveness to IVIg therapy in KD.  
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As the inhibitory FcγRIIB counteracts activation-associated signaling, it had been 
proposed that functional polymorphisms in FCGR2B might determine IVIg 
responders. In fact, increased FCGR2B promoter activity due to high numbers of A 
alleles upstream of the translation start site of FCGR2B was associated with IVIg 
response in KD patients [8]. As FcγRIIA and FcγRIIB are co-expressed on innate 
immune cells, the intensity of expression of these two receptors and their activity 
determine the severity of inflammatory response to IgG immune complexes.  
Further studies are required to determine if epigenetic changes in FCGR2A could be 
used to predict IVIg response in other pathologies. The signaling pathways that lead 
to the inflammatory response often vary among the pathologies and even patients. As 
IVIg is also beneficial in T-cell mediated inflammatory pathologies, FcγR-related 
biomarkers might only prove useful in diseases where autoantibodies are implicated 
in the pathogenesis. High expression levels of interferon-γ (IFN-γ) were associated 
with poor response to IVIg in childhood ITP [9]. Prominent peripheral mobilization of 
HLA-DRhighCD138lowCXCR4low immature plasma cells by day 7 post-IVIg therapy 
was correlated with strong clinical improvement in patients with GBS [10]. 
Importantly, such plasmacytosis was also observed in patients with chronic 
inflammatory demyelinating polyneuropathy, myasthenia gravis and inflammatory 
myopathies [10]. Hence, the quest for universal biomarker(s) that predict IVIg 
responsiveness should continue, and the search should focus on innate/adaptive 
immune cells and their cytokines and molecular regulators. Pre-IVIg levels of IL-17A 
in the circulation could be used to predict response to IVIg. Although there are 
differences in IVIg products from different suppliers, in general they are quite similar 
in therapeutic efficacy and anti-inflammatory mechanisms. Therefore, potential 
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biomarkers would (and should) not vary for each IVIg product that is available for the 
therapy. 
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Figure legend 
 
Figure 1. Examples of molecular and immunological biomarkers reported to 
predict response to IVIg therapy. The majority of the data presented in the figure 
has been derived from studies of patients with Kawasaki disease (KD). In the figure, 
putative biomarkers of poor response to IVIg are depicted in red boxes. The elevated 
levels of DAMPs (such as HMGB1, S100A8 and S100A9) released from stressed 
cells, and G-CSF, released from vascular endothelial cells and smooth muscle cells, 
were reported to predict poor response to IVIg. G-CSF stimulates granulopoiesis and 
granulocyte differentiation by signaling via STAT3. Hypomethylation in five CpG 
sites of FCGR2A predicts IVIg resistance. NF-κB signaling activated by DAMPS via 
TLR and RAGE, and by IgG-immune complexes via FcγRIIA, lead to activation of 
innate immune cells such as neutrophils, macrophages and dendritic cells. These cells 
then secrete high levels of inflammatory mediators such as IL-6, IL-1β, TNF, PRV-1 
and MMP-8. IL-1β stimulates vascular endothelial cells to produce G-CSF. Pre-IVIg 
levels of these inflammatory mediators were also used to predict IVIg response.  
Abbreviations: DAMPs, damage associated molecular pattern molecules; G-CSF, 
granulocyte-colony stimulating factor; G-CSF-R, granulocyte-colony stimulating 
factor receptor; HMGB1,	   high-mobility group box-1; IVIg, intravenous 
immunoglobulin G; MMP-8, matrix metalloproteinase-8; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; PRV-1,	  polycythemia rubra vera-1; 
RAGE, receptor for advanced glycation end products; STAT-3, signal transducer and 
activator of transcription 3; TLR,	  Toll-like receptor; TNF, tumor necrosis factor. 
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